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284 Is there a relationship between stress urinary incontinence and
back pain in the Manchester Adult Cystic Fibrosis Centre female
population?
J.E. Ashbrook1, R. McVean1, A. Jones1. 1Univerity Hospital South Manchester,
Manchester Adult Cystic Fibrosis Centre, Manchester, United Kingdom
Introduction: Musculoskeletal problems and stress urinary incontinence (UI) have
long been identiﬁed as complications of an ageing Cystic Fibrosis (CF) population.
More recently links between back pain, respiratory disorders and stress UI have
been reported in a general population of 38,050 women [1].
Aims: To investigate associations between back pain and stress UI and discuss
pelvic ﬂoor weakness as a contributor to back pain in the female patient population
at MACFC.
Method: Data was extracted from the physiotherapy records of 138 female patients
from information recorded at annual assessment, musculoskeletal and women’s
health appointments.
Results: 52 (38%) females complained of both stress UI and back pain, 28 (20%)
complained of stress UI without back pain and 20 (14%) complained of back pain
without stress UI. 49 (36%) of the patients had been taught pelvic ﬂoor exercises.
Of these, 10 (20%) reported no improvement in their symptoms, 19 (39%) improved
in both stress UI and back pain, 13 (27%) improved in stress UI only and 7 (14%)
improved in back pain only.
Conclusion: This study has conﬁrmed that stress UI and back pain are prevalent in
this population with 72% complaining of symptoms. The data has also suggested
a strong link between the two conditions with 52% of the symptomatic population
complaining of both stress UI and back pain. Of the 49 patients that were taught
pelvic ﬂoor strengthening exercises 39 (80%) reported improvement in their UI,
back pain or both. This leads to the suggestion that strengthening the pelvic ﬂoor
will help both stress UI and back pain in the study population.
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R.L. Dentice1, M.R. Elkins1, P.T. Bye1. 1Royal Prince Alfred Hospital, Sydney,
NSW, Australia
Objectives: To determine whether the timing of DNase inhalation affects clinical
outcomes in people with CF, speciﬁcally examining before vs after airway clearance
techniques; morning vs evening; and long vs short dwell time.
Method: Relevant randomised and quasi-randomised controlled trials were iden-
tiﬁed from the Physiotherapy Evidence Database (PEDro), Google Scholar and
international CF conference proceedings. Relevant data were extracted and, where
possible, meta-analysed.
Results: The searches identiﬁed 87 trials, of which 6 trials (involving 140 partici-
pants) met our inclusion criteria. All 6 studies used a cross-over design. Intervention
periods ranged from 2 to 8 weeks. Inhalation after instead of before airway
clearance did not change FEV1 (SMD −0.22, 95%CI −1.36 to 0.93). Similarly, FVC
and quality of life were unaffected. Some secondary outcomes were statistically
signiﬁcant in individual studies (eg MEF25 was signiﬁcantly higher with inhalation
before airway clearance), but these have not been conﬁrmed by other studies. In one
trial, morning vs evening inhalation had no impact on lung function or symptoms.
In another trial, allowing DNase to dwell in the lungs longer (mean 11 hr) before
airway clearance improved FEF25−75 and QOL signiﬁcantly more than a short
dwell time (0.2 hr).
Conclusion: The primary outcome examined by this review (FEV1) was not
affected by the timing of DNase inhalation with respect to airway clearance, time
of day, or dwell time. For the other outcomes of this review, there were some
signiﬁcant ﬁndings in individual studies, but further evidence is required.
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Aim: To compare the effect of two positioning regimens during inhalation of a
nebulised aerosol on the proportion of the loaded dose that deposits in the lungs,
the uniformity of deposition, and the ratio of apical:non-apical deposition in people
with CF and healthy controls.
Method: 13 adults (mean±SD age 30±6 y) with stable CF lung disease
(FEV1%pred 50±21, range 25−88) and 13 adults (28±5 y) with normal lung
function inhaled a 4mL nebulised radioaerosol for 20min on two days. Participants
were randomised to sit upright for one nebulisation, and to alternate between left
and right side lying at 2min intervals during the other nebulisation. After each
nebulisation, a transmission scan identiﬁed the three-dimensional margin of the lung
ﬁelds and a gamma camera scanned the distribution of the deposited radioaerosol.
Results: The proportion of the loaded dose that deposits in the lungs in sitting
was similar in CF (13±4%) and controls (11±6%), and was unaltered by sidelying
in either group (11±3% and 11±6%, respectively). The deposition pattern was
signiﬁcantly less uniform in CF (variance in counts/voxel, 2156±753) than in
healthy controls (1294±920) p = 0.015. This was unaltered by sidelying in either
group. Deposition was signiﬁcantly less concentrated in the apical regions than
the rest of the lung, with apical:non-apical concentrations of 0.38±0.10 in CF
and 0.44±0.18 in controls. Importantly, side lying signiﬁcantly improved apical
deposition in controls to 0.48±0.16 (p = 0.02), but not in CF (0.47±0.19%).
Conclusion: Side lying signiﬁcantly improved apical deposition in healthy lungs
with no negative impact in CF. Further research is needed in milder CF lung disease.
287 Can modern nebulisers improve patient outcomes?
L. Morrison1, I. Paterson1, G. MacGregor1. 1Gartnavel General Hospital, West of
Scotland Adult CF Unit, Glasgow, United Kingdom
Aim: To evaluate whether the introduction of modern nebulisers using Vibrating
Mesh Technology (VMT) has a signiﬁcant impact on lung function in adults with
Cystic Fibrosis (CF).
Method: Retrospective analysis of patients in an adult CF centre who used a
nebuliser. We considered respiratory function (FEV1 and FVC) 6 months pre
introduction of the VMT device and 6 months post. In addition we reviewed
frequency of exacerbation (prescription of IV or oral antibiotics), and considered
patient satisfaction with the device used.
Results: 118 patients (age 15−66 yr) used a nebuliser: 45% (n = 53) used E-Flow,
37% (n = 44) used I-neb and 18% (n = 21) used Portaneb. Some data were incom-
plete due to patient transfer or archiving of notes rendering them unavailable for
review, full analysis was therefore available for 62 patients using I-neb or E-Flow.
There was no signiﬁcant difference in FEV1or FVC between implementation of
the device and the end of a 12 month evaluation period; median FEV1 pre 1.76 L,
post 1.79 L, p = 0.907. There was no signiﬁcant difference between frequencies of
exacerbation during the evaluation period.
Patients using the E-ﬂow considered it time efﬁcient and were extremely satisﬁed.
Of the I-neb users, one discontinued use; citing actively breathing on the device
as “too difﬁcult” preferring the conventional portaneb. All others were extremely
satisﬁed. The 96 remaining patients continue with their VMT. Patients reported
improvement in adherence with nebulisation due to the delivery speed of the VMT,
although this could not be formally assessed.
Conclusion: Modern nebuliser devices alone do not have a signiﬁcant impact on
the progressive nature of CF lung disease.
